|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Collaboration revenue | ||||
| Operating expenses: | ||||
| Research and development | ||||
| In-process research and development | ||||
| General and administrative | ||||
| Depreciation | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other income: | ||||
| Change in fair value of convertible promissory notes | ||||
| Other income | ||||
| Pre-tax loss | ||||
| Income tax (expense) benefit | ||||
| Net loss | ||||
| Share information: | ||||
| Net loss per share of common stock, basic | ||||
| Net loss per share of common stock, diluted | ||||
| Weighted-average shares of common stock outstanding, basic | ||||
| Weighted-average shares of common stock outstanding, diluted |
Loading...
